Cartesian Therapeutics In logo

Cartesian Therapeutics In share price today

(RNAC)

Cartesian Therapeutics In share price is $17.63 & ₹1,512.83 as on 7 Jan 2025, 2.30 'hrs' IST

$17.63

0.78

(4.63%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Cartesian Therapeutics In share price in Dollar and Rupees. Guide to invest in Cartesian Therapeutics In stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Cartesian Therapeutics In, along with analyst recommendations, forecasts, and comprehensive financials.

Cartesian Therapeutics In share price movements

  • Today's Low: $16.40
    Today's High: $17.95

    Day's Volatility :8.64%

  • 52 Weeks Low: $11.67
    52 Weeks High: $41.87

    52 Weeks Volatility :72.14%

Cartesian Therapeutics In Returns

PeriodCartesian Therapeutics InIndex (Russel 2000)
3 Months
-30.14%
0.0%
6 Months
0.42%
0.0%
1 Year
-14.9%
0.0%
3 Years
1365.22%
-19.8%

Cartesian Therapeutics In Key Statistics

in dollars & INR

Previous Close
$16.85
Open
$16.88
Today's High
$17.95
Today's Low
$16.4
Market Capitalization
$430.3M
Today's Volume
$111.7K
52 Week High
$41.87
52 Week Low
$11.665
Revenue TTM
$47.9M
EBITDA
$-39.8M
Earnings Per Share (EPS)
$-47.22
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.54%
Return On Equity TTM
-7029.26%

How to invest in Cartesian Therapeutics In from India?

It is very easy for Indian residents to invest directly in Cartesian Therapeutics In from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cartesian Therapeutics In stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cartesian Therapeutics In or RNAC on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cartesian Therapeutics In or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cartesian Therapeutics In shares which would translate to 0.049 fractional shares of Cartesian Therapeutics In as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cartesian Therapeutics In, in just a few clicks!

Returns in Cartesian Therapeutics In for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Cartesian Therapeutics In investment value today

Current value as on today

₹92,263

Returns

₹7,737

(-7.74%)

Returns from Cartesian Therapeutics In Stock

₹10,960 (-10.96%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Cartesian Therapeutics In

-81%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Cartesian Therapeutics In on INDmoney from India has reduced in the last 30 days as on Jan 7, 2025. -81% less investors are searching Cartesian Therapeutics In in the last 30 days versus the previous period.

Global Institutional Holdings in Cartesian Therapeutics In

  • FMR Inc

    11.22%

  • MPM Oncology Impact Management LP

    2.48%

  • Siren, L.L.C.

    2.25%

  • BlackRock Inc

    1.60%

  • Citadel Advisors Llc

    1.48%

  • JPMorgan Chase & Co

    1.22%

Analyst Recommendation on Cartesian Therapeutics In

Buy

    90%Buy

    9%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Cartesian Therapeutics In(by analysts ranked 0 to 5 stars)

Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
7
9
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Cartesian Therapeutics In

What analysts predicted

Upside of 143.9%

Current:

$17.63

Target:

$43.00

Insights on Cartesian Therapeutics In

  • Price Movement

    In the last 7 days, RNAC stock has moved down by -10.2%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 33.44M → 387.0K (in $), with an average decrease of 98.8% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 13.83M → -24.18M (in $), with an average decrease of 274.8% per quarter
  • RNAC vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 23.7% return, outperforming this stock by 33.6%
  • Price to Sales

    ForRNAC every $1 of sales, investors are willing to pay $4.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Cartesian Therapeutics In Financials in INR & Dollars

FY18Y/Y Change
Revenue
$903.0K
↑ 336.23%
Net Income
$-65.3M
↑ 0.02%
Net Profit Margin
-7.2K%
↑ 24320.6%
FY19Y/Y Change
Revenue
$6.7M
↑ 639.42%
Net Income
$-55.4M
↓ 15.28%
Net Profit Margin
-828.97%
↑ 6406.47%
FY20Y/Y Change
Revenue
$16.6M
↑ 148.57%
Net Income
$-68.9M
↑ 24.44%
Net Profit Margin
-414.99%
↑ 413.98%
FY21Y/Y Change
Revenue
$85.1M
↑ 412.6%
Net Income
$-25.7M
↓ 62.71%
Net Profit Margin
-30.19%
↑ 384.8%
FY22Y/Y Change
Revenue
$110.8M
↑ 30.21%
Net Income
$35.4M
↓ 237.73%
Net Profit Margin
31.94%
↑ 62.13%
FY23Y/Y Change
Revenue
$26.0M
↓ 76.53%
Net Income
$-219.7M
↓ 721.02%
Net Profit Margin
-844.91%
↓ 876.85%
Q2 FY23Q/Q Change
Revenue
$5.2M
↓ 11.6%
Net Income
$-11.4M
↓ 47.44%
Net Profit Margin
-216.94%
↑ 147.88%
Q3 FY23Q/Q Change
Revenue
$6.6M
↑ 24.8%
Net Income
$-9.0M
↓ 20.94%
Net Profit Margin
-137.41%
↑ 79.53%
Q4 FY23Q/Q Change
Revenue
$8.3M
↑ 26.18%
Net Income
$-177.7M
↑ 1873.54%
Net Profit Margin
-2.1K%
↓ 2011.85%
Q1 FY24Q/Q Change
Revenue
$5.8M
↓ 29.35%
Net Income
$-56.8M
↓ 68.01%
Net Profit Margin
-973.01%
↑ 1176.25%
Q2 FY24Q/Q Change
Revenue
$33.4M
↑ 472.69%
Net Income
$13.8M
↓ 124.35%
Net Profit Margin
41.37%
↑ 1014.38%
Q3 FY24Q/Q Change
Revenue
$387.0K
↓ 98.84%
Net Income
$-24.2M
↓ 274.78%
Net Profit Margin
-6.2K%
↓ 6290.21%
FY18Y/Y Change
Profit
$903.0K
↑ 336.23%
FY19Y/Y Change
Profit
$6.7M
↑ 639.42%
FY20Y/Y Change
Profit
$16.6M
↑ 148.57%
FY21Y/Y Change
Profit
$85.1M
↑ 412.6%
FY22Y/Y Change
Profit
$108.7M
↑ 27.81%
FY23Y/Y Change
Profit
$24.5M
↓ 77.51%
Q2 FY23Q/Q Change
Profit
$4.6M
↓ 13.13%
Q3 FY23Q/Q Change
Profit
$6.4M
↑ 37.62%
Q4 FY23Q/Q Change
Profit
$8.0M
↑ 25.65%
Q1 FY24Q/Q Change
Profit
$5.7M
↓ 29.23%
Q2 FY24Q/Q Change
Profit
$33.2M
↑ 487.75%
Q3 FY24Q/Q Change
Profit
$387.0K
↓ 98.84%
FY18Y/Y Change
Operating Cash Flow
$-59.2M
↑ 13.69%
Investing Cash Flow
$25.3M
↓ 1304.58%
Financing Cash Flow
$697.0K
↓ 98.94%
FY19Y/Y Change
Operating Cash Flow
$-51.4M
↓ 13.06%
Investing Cash Flow
$229.0K
↓ 99.09%
Financing Cash Flow
$105.0M
↑ 14970.44%
FY20Y/Y Change
Operating Cash Flow
$34.9M
↓ 167.82%
Investing Cash Flow
$-741.0K
↓ 423.58%
Financing Cash Flow
$14.4M
↓ 86.26%
FY21Y/Y Change
Operating Cash Flow
$-60.4M
↓ 273.11%
Investing Cash Flow
$-17.1M
↑ 2213.09%
Financing Cash Flow
$52.9M
↑ 266.55%
FY22Y/Y Change
Operating Cash Flow
$-31.6M
↓ 47.62%
Investing Cash Flow
$-15.0M
↓ 12.47%
Financing Cash Flow
$39.2M
↓ 25.87%
Q2 FY23Q/Q Change
Operating Cash Flow
$-9.9M
↑ 12.89%
Investing Cash Flow
$28.1M
↓ 0.04%
Financing Cash Flow
$-2.6M
↓ 1835.57%

Cartesian Therapeutics In Technicals Summary

Sell

Neutral

Buy

Cartesian Therapeutics In is currently in a neutral trading position according to technical analysis indicators.

Cartesian Therapeutics In Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cartesian Therapeutics In
-31.03%
0.42%
-14.9%
1365.22%
1365.22%
Regeneron Pharmaceuticals, Inc.
-8.86%
-31.87%
-20.46%
15.59%
87.28%
Biontech Se
-4.16%
43.82%
3.49%
-49.66%
167.6%
Alnylam Pharmaceuticals, Inc.
-8.45%
-8.03%
19.03%
56.02%
98.44%
Vertex Pharmaceuticals Incorporated
-14.11%
-16.23%
-2.87%
81.78%
76.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cartesian Therapeutics In
NA
NA
0.0
-5.02
-70.29
-0.11
NA
0.03
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cartesian Therapeutics In
Buy
$430.3M
1365.22%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
87.28%
17.61
33.61%
Biontech Se
Buy
$27.3B
167.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
98.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
76.8%
32.84
-4.51%

About Cartesian Therapeutics In

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
Organization
Cartesian Therapeutics In
Employees
37
CEO
Dr. Carsten Brunn Ph.D.
Industry
Miscellaneous

Management People of Cartesian Therapeutics In

NameTitle
Dr. Carsten Brunn Ph.D.
President, CEO & Director
Mr. Blaine T. Davis
Chief Financial Officer
Dr. Metin Kurtoglu M.D., Ph.D.
Chief Technology Officer
Dr. Chris Jewell Ph.D.
Chief Scientific Officer
Mr. Matthew Bartholomae J.D.
General Counsel & Secretary
Dr. Milos Miljkovic M.D., Ph.D.
Chief Medical Officer
Dr. Emily English Ph.D.
SVP & Head of Manufacturing

Important FAQs about investing in Cartesian Therapeutics In from India :

What is Cartesian Therapeutics In share price today?

Cartesian Therapeutics In share price today stands at $17.63, Open: $16.88 ; Previous Close: $16.85 ; High: $17.95 ; Low: $16.40 ; 52 Week High: $41.87 ; 52 Week Low: $11.67. The stock opens at $16.88, after a previous close of $16.85. The stock reached a daily high of $17.95 and a low of $16.40, with a 52-week high of $41.87 and a 52-week low of $11.67.

Can Indians buy Cartesian Therapeutics In shares?

Yes, Indians can invest in the Cartesian Therapeutics In (RNAC) from India.

With INDmoney, you can buy Cartesian Therapeutics In at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Cartesian Therapeutics In at zero transaction cost.

How can I buy Cartesian Therapeutics In shares from India?

It is very easy to buy Cartesian Therapeutics In from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cartesian Therapeutics In be purchased?

Yes, you can buy fractional shares of Cartesian Therapeutics In with INDmoney app.

What are the documents required to start investing in Cartesian Therapeutics In stocks?

To start investing in Cartesian Therapeutics In, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Cartesian Therapeutics In

Today’s highest price of Cartesian Therapeutics In (RNAC) is $17.95.

Today’s lowest price of Cartesian Therapeutics In (RNAC) is $16.40.

What is today's market capitalisation of Cartesian Therapeutics In

Today's market capitalisation of Cartesian Therapeutics In RNAC is 430.3M

What is the 52 Week High and Low Range of Cartesian Therapeutics In

  • 52 Week High

    $41.87

  • 52 Week Low

    $11.67

What are the historical returns of Cartesian Therapeutics In?

  • 1 Month Returns

    -31.03%

  • 3 Months Returns

    0.42%

  • 1 Year Returns

    -14.9%

  • 5 Years Returns

    1365.22%

Who is the Chief Executive Officer (CEO) of Cartesian Therapeutics In

Dr. Carsten Brunn Ph.D. is the current Chief Executive Officer (CEO) of Cartesian Therapeutics In.